Noble trial left main

News Daily News. By Todd Neale. Created with Sketch. December 23, He got his start in journalism at … Read Full Bio. Disclosures NOBLE was funded by the participating centers and by Biosensors, which provided an unrestricted institutional research grant. Yeh reports having investigator-initiated research grants and serving on scientific advisory boards for Abbott Vascular, Boston Scientific, and Medtronic.

CAD Pharma. Cardiac Surgery. Cath Lab. Never Miss a Beat Stay up-to-date with breaking news, conference slides, and topical videos covering the spectrum of CVD.

Forgot Password. Forgot Your Password? Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis NOBLE : a prospective, randomised, open-label, non-inferiority trial.

Presented by Dr. Evald H. Total number of enrollees: 1, Duration of follow-up: 5 years Mean patient age: Please enter your comment! Please enter your name here. You have entered an incorrect email address!

First clinical results for Tria biopolymer valve published 21st December Understanding the risk of acute kidney injury in the cath lab 10th December What to expect from AHA 12th November Mirvat Alasnag 26th November Christoph Naber 13th September Secondary endpoints included all-cause mortality, non-procedural myocardial infarction, and repeat revascularisation.

Outcomes were analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.